4588 — Oncolys Biopharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapMomentum Trap

Annual income statement for Oncolys Biopharma, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	314	642	976	63	31.4
Cost of Revenue
Gross Profit	236	199	338	30.6	31.4
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	2,357	2,208	2,185	2,015	1,730
Operating Profit	-2,042	-1,565	-1,209	-1,952	-1,699
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-2,091	-1,612	-1,146	-1,936	-1,681
Provision for Income Taxes
Net Income After Taxes	-2,095	-1,615	-1,149	-1,939	-1,685
Net Income Before Extraordinary Items
Net Income	-2,095	-1,615	-1,149	-1,939	-1,685
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-2,095	-1,615	-1,149	-1,939	-1,685
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-129	-91.2	-66.9	-108	-76.7
Dividends per Share